• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA for versatile labeling with Sc, Cu, Ga and Lu.

作者信息

Greifenstein Lukas, Grus Tilmann, Nagel Johannes, Sinnes Jean Phillip, Rösch Frank

机构信息

Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz.

Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz.

出版信息

Appl Radiat Isot. 2020 Feb;156:108867. doi: 10.1016/j.apradiso.2019.108867. Epub 2019 Aug 16.

DOI:10.1016/j.apradiso.2019.108867
PMID:31883763
Abstract
摘要

相似文献

1
Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA for versatile labeling with Sc, Cu, Ga and Lu.一种含方酸的PSMA抑制剂与AAZTA偶联物的合成与标记，用于用钪、铜、镓和镥进行多功能标记。
Appl Radiat Isot. 2020 Feb;156:108867. doi: 10.1016/j.apradiso.2019.108867. Epub 2019 Aug 16.
2
Ga, Sc and Lu-labeled AAZTA-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues.镓、钪和镥标记的AAZTA-PSMA-617：与DOTA-PSMA-617类似物相比的合成、放射性标记、稳定性及细胞结合情况
EJNMMI Radiopharm Chem. 2020 Nov 26;5(1):28. doi: 10.1186/s41181-020-00107-8.
3
AAZTA/AAZTA-TOC: synthesis and radiochemical evaluation with Ga, Sc and Lu.AAZTA/AAZTA-TOC：镓、钪和镥的合成及放射化学评估
EJNMMI Radiopharm Chem. 2019 Aug 1;4(1):18. doi: 10.1186/s41181-019-0068-1.
4
Clinical Translation and First In-Human Use of [Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.[钪]Sc-PSMA-617用于转移性去势抵抗性前列腺癌PET成像的临床转化及首次人体应用
Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.
5
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.68Ga- 和 177Lu-标记的 PSMA I&T：PSMA 靶向治疗概念的优化及首例概念验证人体研究。
J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.
6
[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.[44Sc]Sc-PSMA-617 示踪剂在转移性去势抵抗性前列腺癌患者中的生物分布和剂量学研究。
Clin Nucl Med. 2018 May;43(5):323-330. doi: 10.1097/RLU.0000000000002003.
7
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.使用转移性去势抵抗性前列腺癌患者中的 [44Sc]Sc-PSMA-617 药代动力学预测 [177Lu]Lu-PSMA-617 对正常器官的吸收剂量。
Clin Nucl Med. 2018 Jul;43(7):486-491. doi: 10.1097/RLU.0000000000002102.
8
Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Ga, In, Lu and Ac.评估携带新型螯合物的PSMA靶向配体在诊疗学中的应用：镓、铟、镥和锕的稳定性及络合动力学
Nucl Med Biol. 2017 Dec;55:38-46. doi: 10.1016/j.nucmedbio.2017.10.001. Epub 2017 Oct 3.
9
In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector.体内外评价双功能螯合剂 NODIA-Me 与前列腺特异性膜抗原靶向载体的结合。
Nucl Med Biol. 2018 May;60:45-54. doi: 10.1016/j.nucmedbio.2018.03.002. Epub 2018 Mar 10.
10
The Ga/Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV values and absorbed dose estimates.镓/镥治疗诊断一体化概念在去势抵抗性前列腺癌的前列腺特异性膜抗原靶向治疗中的应用：标准化摄取值与吸收剂量估计值的相关性
Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12.

引用本文的文献

1
First-in-human study of an optimized, potential kit-type, SSTR antagonist Ga-DATA-LM4 in patients with metastatic neuroendocrine tumors.优化后的潜在试剂盒型生长抑素受体拮抗剂Ga-DATA-LM4在转移性神经内分泌肿瘤患者中的首次人体研究。
Theranostics. 2025 Jan 20;15(6):2510-2522. doi: 10.7150/thno.94521. eCollection 2025.
2
Squaric Acid Bisphposphonates for Theranostics of Bone Metastasis - the Easy DOTA-Zoledronate.用于骨转移诊疗的方形酸双膦酸盐——简便的DOTA-唑来膦酸。
Front Nucl Med. 2022 May 10;2:870910. doi: 10.3389/fnume.2022.870910. eCollection 2022.
3
Scandium Radioisotopes-Toward New Targets and Imaging Modalities.
钪放射性同位素——迈向新的靶点和成像方式。
Molecules. 2023 Nov 19;28(22):7668. doi: 10.3390/molecules28227668.
4
The effects of novel macrocyclic chelates on the targeting properties of the Ga-labeled Gastrin releasing peptide receptor antagonist RM2.新型大环螯合物对镓标记的胃泌素释放肽受体拮抗剂RM2靶向特性的影响
EJNMMI Res. 2023 Jun 7;13(1):56. doi: 10.1186/s13550-023-01005-1.
5
Translational assessment of a DATA-functionalized FAP inhibitor with facile Ga-labeling at room temperature.室温下易于 Ga 标记的 DATA 功能化 FAP 抑制剂的转化评估。
Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3202-3213. doi: 10.1007/s00259-023-06285-2. Epub 2023 Jun 7.
6
[In]In/[Lu]Lu-AAZTA-LM4 SSTR-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results.用于癌症诊疗的[铟]铟/[镥]镥-AAZTA-LM4生长抑素受体拮抗剂：从临床前测试到首例患者结果
Pharmaceutics. 2023 Feb 26;15(3):776. doi: 10.3390/pharmaceutics15030776.
7
Modern Developments in Bifunctional Chelator Design for Gallium Radiopharmaceuticals.双功能螯合剂设计用于镓放射性药物的现代进展。
Molecules. 2022 Dec 26;28(1):203. doi: 10.3390/molecules28010203.
8
Boosting Bismuth(III) Complexation for Targeted α-Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA.用中孔螯合剂 AAZTA 增强铋(III)配合物用于靶向 α 治疗 (TAT) 应用。
Angew Chem Int Ed Engl. 2022 Oct 24;61(43):e202207120. doi: 10.1002/anie.202207120. Epub 2022 Sep 29.
9
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [Ga]Ga-DATA.SA.FAPi.从自动合成到[镓]镓-DATA.SA.FAPi在多种癌症中的体内应用——临床结果
Pharmaceuticals (Basel). 2022 Aug 14;15(8):1000. doi: 10.3390/ph15081000.
10
Cold Kit Labeling: The Future of Ga Radiopharmaceuticals?冷试剂盒标签：镓放射性药物的未来？
Front Med (Lausanne). 2022 Feb 10;9:812050. doi: 10.3389/fmed.2022.812050. eCollection 2022.